<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01826123</url>
  </required_header>
  <id_info>
    <org_study_id>343/12</org_study_id>
    <nct_id>NCT01826123</nct_id>
  </id_info>
  <brief_title>Point-of-Care Testing in Coagulopathic Patients Undergoing Cardiac Surgery - a Multicenter Study</brief_title>
  <acronym>MultiPOC</acronym>
  <official_title>Point-of-Care Testing - A Prospective, Randomized, Controlled Multicenter Study of Efficacy in Coagulopathic Cardiac Surgery Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Goethe University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Goethe University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, the investigators study group showed in a mono center study that Point of Care
      (POC) based hemotherapy may reduce transfusion rates of allogenic blood products in
      perioperative care of coagulopathic cardiac surgery patients. The investigators aim to verify
      the obtained results by conducting this multicenter study.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>packed red blood cell concentrate (PRBC) transfusion rate</measure>
    <time_frame>During the period between inclusion into the study and 24 h after postoperative admission to ICU</time_frame>
    <description>Number of transfused units of PRBC during the period between inclusion into the study and 24 hours (h) after admission to ICU.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transfusion rate of Fresh Frozen Plasma</measure>
    <time_frame>During the period between inclusion into the study and 24 h after postoperative admission to ICU</time_frame>
    <description>Number of transfused units of Fresh Frozen Plasma (FFP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Blood loss</measure>
    <time_frame>for up to 24 h after postoperative admission to ICU</time_frame>
    <description>Blood loss 6h, 12h and 24h after postoperative admission to ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>after postoperative admission to ICU, an expected average of 30 hours</time_frame>
    <description>Duration of postoperative mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Horovitz - indices</measure>
    <time_frame>for up to 24 h after postoperative admission to ICU</time_frame>
    <description>PaO2/FiO2 - indices at admission to ICU, as well as 2h, 4h, 12h and 24 h after admission to ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute renal failure</measure>
    <time_frame>during treatment at the intensive care unit, for an average of 3 weeks</time_frame>
    <description>Incidence of acute renal failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalisation</measure>
    <time_frame>From admission to ICU and up to discharge from the hospital, an expected average of 10 days</time_frame>
    <description>duration of ICU treatment duration of IMC (Intermediate Care) treatment duration of hospitalisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rethoracotomies</measure>
    <time_frame>During the period between inclusion into the study and 24 h after postoperative admission to ICU</time_frame>
    <description>number of patients with rethoracotomies. Cause for rethoracotomies (surgical or coagulopathic bleeding, pericardium tamponade)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic or allergic adverse events</measure>
    <time_frame>for up to 24 h after postoperative admission to ICU</time_frame>
    <description>Number of patients with thromboembolic or allergic adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator - associated pneumonia</measure>
    <time_frame>after postoperative admission to ICU up to discharge from ICU, an expected average of 5 days</time_frame>
    <description>Number of patients with ventilator - associated pneumonia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Sepsis</measure>
    <time_frame>after postoperative admission to ICU up to discharge from ICU, an expected average of 5 days</time_frame>
    <description>Number of patients with postoperative Sepsis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion rate of platelet concentrates</measure>
    <time_frame>During the period between inclusion into the study and 24 h after postoperative admission to ICU</time_frame>
    <description>Number of transfused platelet concentrates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Age of each platelet concentrate</measure>
    <time_frame>During the period between inclusion into the study and 24 h after postoperative admission to ICU</time_frame>
    <description>age (days) of each platelet concentrates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of infused PCC</measure>
    <time_frame>During the period between inclusion into the study and 24 h after postoperative admission to ICU</time_frame>
    <description>Amount of infused prothrombin complex concentrates (PCC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of infused rVIIa</measure>
    <time_frame>During the period between inclusion into the study and 24 h after postoperative admission to ICU</time_frame>
    <description>Amount of infused activated coagulation factor VII (rVIIa)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of infused fibrinogen concentrate</measure>
    <time_frame>During the period between inclusion into the study and 24 h after postoperative admission to ICU</time_frame>
    <description>Amount of infused fibrinogen concentrate</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Preoperative antiaggregatory medication</measure>
    <time_frame>at the day before surgery</time_frame>
    <description>number of patients with preoperative intake of any antiaggregatory medication. kind of antiaggregatory medication.</description>
  </other_outcome>
  <other_outcome>
    <measure>infused crystalloid and colloid volume</measure>
    <time_frame>intraoperatively and for up to 24 h after admission to ICU</time_frame>
    <description>Amount of infused crystalloid and colloid volume. kind of crystalloid and colloid volume.</description>
  </other_outcome>
  <other_outcome>
    <measure>Age</measure>
    <time_frame>at the day before surgery</time_frame>
    <description>age of the patient</description>
  </other_outcome>
  <other_outcome>
    <measure>euroSCORE</measure>
    <time_frame>at the day before surgery</time_frame>
    <description>perioperative risk assessment</description>
  </other_outcome>
  <other_outcome>
    <measure>Weight</measure>
    <time_frame>at the day before surgery</time_frame>
    <description>Weight of the patient</description>
  </other_outcome>
  <other_outcome>
    <measure>Height</measure>
    <time_frame>at the day before surgery</time_frame>
    <description>height of the patient</description>
  </other_outcome>
  <other_outcome>
    <measure>ASA score</measure>
    <time_frame>at the day before surgery</time_frame>
    <description>Preoperatively assessed anesthesia risk score</description>
  </other_outcome>
  <other_outcome>
    <measure>clamping time</measure>
    <time_frame>intraoperatively</time_frame>
    <description>Duration of intraoperative clamping of the aorta</description>
  </other_outcome>
  <other_outcome>
    <measure>CPB time</measure>
    <time_frame>intraoperatively</time_frame>
    <description>Duration of extracorporeal circulation intraoperatively</description>
  </other_outcome>
  <other_outcome>
    <measure>Priming volume</measure>
    <time_frame>intraoperatively</time_frame>
    <description>Volume of the priming volume of the extracorporeal circulation</description>
  </other_outcome>
  <other_outcome>
    <measure>INR</measure>
    <time_frame>preoperatively and up to 24 h after admission to ICU</time_frame>
    <description>International Normalized Ratio</description>
  </other_outcome>
  <other_outcome>
    <measure>aPTT</measure>
    <time_frame>preoperatively and up to 24 h after admission to ICU</time_frame>
    <description>activated partial prothrombin time [sec]</description>
  </other_outcome>
  <other_outcome>
    <measure>Platelet count</measure>
    <time_frame>preoperatively and up to 24 h after admission to ICU</time_frame>
    <description>platelet count</description>
  </other_outcome>
  <other_outcome>
    <measure>CT</measure>
    <time_frame>Intraoperatively and up to 24 h after admission to ICU</time_frame>
    <description>Clotting time in the EXTEM and INTEM test of the Rotem device</description>
  </other_outcome>
  <other_outcome>
    <measure>MCF</measure>
    <time_frame>intraoperatively and up to 24h after admission to ICU</time_frame>
    <description>Maximal clot firmness in the EXTEM- and INTEM test of the ROTEM device</description>
  </other_outcome>
  <other_outcome>
    <measure>AUC</measure>
    <time_frame>intraoperatively and up to 24h after admission to ICU</time_frame>
    <description>Area under the aggregation curve in the Multiplate device following stimulation with arachidonic acid or adenosine disphosphate.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Coagulopathy During Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Conventional laboratory testing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After being randomized to the group &quot;conventional coagulating testing&quot;, hemostatic therapy will be based exclusively on conventional standard coagulation analyses like International normalized ratio (INR), activated prothrombin time (aPTT), fibrinogen and platelet concentration or Activated clotting time (ACT. Analyses will be performed at i) fixed time points (preoperative and at admission to ICU) and ii) variable timepoints depending on the decision of the attending physician. Hemostatic therapy will be based on a specific hemostatic therapy algorithm. Intraoperatively, analyses of ACT (activated clotting time) and INR will be performed following institutional standards using specific POC tests.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>POC testing (ROTEM and Multiplate)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After being randomized to the group &quot;POC testing&quot;, hemostatic therapy will be based exclusively on POC measures obtained by i) viscoelastic tests (ROTEM(R), TEM international, Munich, Germany) and aggregometric tests (multiplate, ROCHE AG, Grenzach, Germany). Analyses will be performed at variable timepoints depending on the decision of the attending physician. Hemostatic therapy will be based on a specific hemostatic therapy algorithm. Intraoperatively, analyses of ACT (activated clotting time) and INR will be performed following institutional standards using specific POC tests.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Conventional laboratory testing (Central laboratory)</intervention_name>
    <description>aPTT, INR, fibrinogen concentration, platelet count</description>
    <arm_group_label>Conventional laboratory testing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>POC testing</intervention_name>
    <description>ROTEM: Clotting time (CT) in the EXTEM- and INTEM-test, Maximal clot firmness in the FIBTEM-test, Clot Lysis Index (CLI) multiplate: Area under the aggregation curve following stimulation with arachidonic acid (ASA) and Adenosine diphosphate (ADP)</description>
    <arm_group_label>POC testing (ROTEM and Multiplate)</arm_group_label>
    <other_name>viscoleastic measures using the ROTEM(R) device and</other_name>
    <other_name>aggregometric measures using the Multiplate(R) device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Step 1:

          -  Patients scheduled for elective, complex cardiothoracic surgery (combined coronary
             artery bypass graft and valve surgery, double or triple valve procedures, aortic
             surgery or redo surgery) with cardiopulmonary bypass (CPB)

        Step 2:

          -  diffuse bleeding after heparin reversal following extracorporeal circulation or

          -  intra- or postoperative blood loss exceeding 250 ml/h or 50 ml/10 min

        Exclusion Criteria:

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian F Weber, MD</last_name>
    <role>Study Director</role>
    <affiliation>Goethe University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kai Zacharowski, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Goethe University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexander Schellhaaß, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Heidelberg University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stefan Hofer, PhD, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Heidelberg University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roland Freynschlag, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Linz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hans Gombotz, PhD, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Linz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Roesner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Rostock</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Linz</name>
      <address>
        <city>Linz</city>
        <state>Oberösterreich</state>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goethe - University</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rostock</name>
      <address>
        <city>Rostock</city>
        <state>Mecklenburg Vorpommern</state>
        <zip>18051</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Weber CF, Görlinger K, Meininger D, Herrmann E, Bingold T, Moritz A, Cohn LH, Zacharowski K. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology. 2012 Sep;117(3):531-47.</citation>
    <PMID>22914710</PMID>
  </reference>
  <reference>
    <citation>Weber CF, Zacharowski K. Perioperative point of care coagulation testing. Dtsch Arztebl Int. 2012 May;109(20):369-75. doi: 10.3238/arztebl.2012.0369. Epub 2012 May 18. Review.</citation>
    <PMID>22685493</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2013</study_first_submitted>
  <study_first_submitted_qc>April 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2013</study_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Goethe University</investigator_affiliation>
    <investigator_full_name>Christian F. Weber, MD</investigator_full_name>
    <investigator_title>Dr. med. Dr. med. habil. Christian Friedrich Weber</investigator_title>
  </responsible_party>
  <keyword>Coagulopathy</keyword>
  <keyword>Hemorrhage</keyword>
  <keyword>Cardiac surgery</keyword>
  <keyword>Point-of-Care testing</keyword>
  <keyword>POC</keyword>
  <keyword>ROTEM</keyword>
  <keyword>multiplate</keyword>
  <keyword>Multiple electrode aggregometry (MEA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Hemostatic Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

